Vermillion's Ovarian Cancer Test Gets FDA OK | GenomeWeb

NEW YORK (GenomeWeb News) – Vermillion has received clearance from the US Food and Drug Administration to market its OVA1 test for helping physicians determine if a woman is at risk for a malignant pelvic mass prior to surgery.

The Fremont, Calif.-based firm developed the test in collaboration with Quest Diagnostics, which has exclusive rights to offer the test to the clinical lab market in the US for three years. It expects the test to be on the market in the fourth quarter of this year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.